News

Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES...

Biosensors BioMatrix

The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents, percutaneous transluminal coronary angioplasty (PTCA) and cutting balloon catheters....

BioSensors International BioFreedom Drug Coated Stent CE mark

Biosensors International has announced CE mark approval for its polymer-free drug-coated stent (DCS), BioFreedom.

Abbott Absorb bioresorbable stent

Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The randomized controlled trial will enroll about 2,250 patients and compare the performance of...

Biosensors International has announced enrollment of the first patient in LEADERS FREE, a clinical study involving BioFreedom, a polymer-free drug-coated stent (DCS) from Biosensors.

abbott Xience Xpedition stent

Abbott announced that the Xience Xpedition everolimus-eluting coronary stent system received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the...

2012 Top 10 Advances in Heart Disease and Stroke Research

Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top...

December 19, 2012 — The first patient has been enrolled in the Boston Scientific EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the Synergy ...

Cook, Zilver PTX, stent, expanding, delivery sheath

The U.S. Food and Drug Administration (FDA) granted market clearance for Cook Medical’s Zilver PTX drug-eluting peripheral stent. It is the first device of its kind on several fronts to go...

Boston Scientific Promus Element Plus Promus Element Drug Eluting Stent

November 9, 2012 — Boston Scientific Corp. has received approval to update the directions for use (DFU) labeling for Promus Element and Promus Element Plus coronary drug eluting stent (DES)...

October 31, 2012 — Boston Scientific Corp. received CE mark approval for the Synergy everolimus-eluting...

The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's ...

As the average age of the U.S. population and the number of patients at high risk for cardiovascular disease increase, the usage of cardio and endovascular stents continues to grow. Interventional...

June 21, 2012 — Plans for a new study involving BioFreedom, the polymer-free drug-coated stent (DCS) from Biosensors, were announced  at EuroPCR by principal investigator Dr. Philip Urban,...

June 15, 2012 — Stentys SA, a medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced that it has...

Evaluating the performance of your cath lab is key to developing a strategic plan for improving service offerings, planning growth and expanding market share to compete for revenues. Availability...

June 4, 2012 — Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) regulatory approval of 32 mm and 38 mm lengths for the Promus Element Plus everolimus-eluting...

May 30, 2012 - According to study results to be featured in the late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific...

May 23, 2012 — Boston Scientific Corp. announces that the Synergy everolimus-eluting bioabsorbable polymer-coated platinum chromium coronary stent demonstrated noninferior results in treating...